cNeuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA dDubowitz Neuromuscular Centre ...

Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from ...

Interim results from a small group of children in a Phase I/II trial are essentially in line with that of Elevidys, according ...

Duchenne muscular dystrophy (DMD) has long been one of the most devastating genetic disorders to affect children. Marked by progressive muscle degeneration, early loss of mobility, and eventual ...

RegenXBio has shared updated phase 1/2 data on its Duchenne muscular dystrophy (DMD) gene therapy, providing evidence that ...

Regenxbio (RGNX) stock in focus as the company shares promising trial data for its RGX-202 gene therapy for Duchenne muscular ...

gstt.sthames.nhs.uk Although bladder function is thought to be unaffected in Duchenne muscular dystrophy, 46/88 boys interviewed had urinary problems. Nine underwent video urodynamics, showing in ...

Abstract: Adults with Duchenne muscular dystrophy (DMD), due to their severe muscular weakness, cannot benefit from passive arm supports that only compensate for the weight of their arms. Active arm ...

In the U.S., ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD ... infusion in patients with deletion mutations involving exon 8 and/or exon 9 in the DMD gene.

LONDON, ON, May 19, 2025 /CNW/ - On May 25, Canadians are walking, running, and rolling in support of the 30th annual Walk to Defeat Duchenne, the country's only national event dedicated to ...

"Sarepta reports outcomes from trial of Duchenne muscular dystrophy therapy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.